JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

11/8/21 7:11:01 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ABUS

Date	Price Target	Rating	Analyst
3/4/2022	$5.50 → $6.00	Buy	Chardan Capital
2/2/2022	$4.00 → $5.00	Hold → Buy	Jefferies
11/8/2021	$7.00 → $9.00	Market Outperform	JMP Securities